XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Assets [Abstract]    
Land $ 16,036,702 $ 15,983,323
Buildings and improvements 103,409,116 102,862,977
Tenant improvements 16,488,963 16,488,066
Lease intangibles 3,475,531 3,776,654
Real estate assets and lease intangibles held for investment, cost 139,410,312 139,111,020
Accumulated depreciation and amortization (34,560,209) (33,700,262)
Real estate assets and lease intangibles held for investment, net 104,850,103 105,410,758
Real estate assets held for sale, net 12,515,912 22,185,742
Real estate assets, net 117,366,015 127,596,500
Other assets:    
Cash, cash equivalents and restricted cash 11,956,853 8,036,496
Deferred leasing costs, net 1,431,607 1,666,135
Goodwill 1,389,000 1,389,000
Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) 29,519 206,177
Deferred tax asset 298,645 298,645
Other Assets, Miscellaneous 2,953,277 3,376,697
Total other assets 18,058,901 14,973,150
TOTAL ASSETS (1) 135,424,916 142,569,650
Liabilities:    
Mortgage notes payable, net 81,525,487 80,977,448
Mortgage notes payable related to properties held for sale, net 12,217,060 21,116,646
Mortgage notes payable, total net 93,742,547 102,094,094
Accounts payable and accrued liabilities 3,794,229 3,290,170
Accrued real estate taxes 1,070,006 1,972,477
Dividends payable 192,232 194,784
Lease liability, net 58,489 64,345
Below-market leases, net 7,047 8,625
Total liabilities 98,864,550 107,624,495
Commitments and contingencies (see Note 10)
Equity:    
Additional paid-in capital 185,805,501 185,770,842
Dividends and accumulated losses (157,688,233) (159,374,010)
Total stockholders' equity before noncontrolling interest 28,255,453 26,535,146
Noncontrolling interest 8,304,913 8,410,009
Total equity 36,560,366 34,945,155
TOTAL LIABILITIES AND EQUITY 135,424,916 142,569,650
Series D Preferred Stock [Member]    
Liabilities:    
Dividends payable 192,232  
Equity:    
Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 984,238 shares issued and outstanding (liquidation preference $25.00 per share) as of March 31, 2025 and 997,082 shares issued and outstanding as of December 31, 2024 9,842 9,971
Common Class A [Member]    
Equity:    
Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 12,834,317 shares and 12,834,317 shares were issued and outstanding at March 31, 2025 and December 31, 2024, respectively $ 128,343 $ 128,343